Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513034 | 0.88 | CTSL (0.53) | SIRT2SIRT1CTSSCTSLCTSB | |
| SCHEMBL4154299 | 0.85 | TACR1 (0.67) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL5178489 | 0.79 | ALDH1A1 (0.55) | SIRT2SIRT1CTSSCTSLCTSB | |
| SCHEMBL11373846 | 0.77 | ITGB3 (0.58) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL15062444 | 0.77 | MEN1 (0.65) | SIRT2SIRT1CTSKSIRT3MEN1 | |
| SCHEMBL18546554 | 0.76 | SIRT2 (0.64) | SIRT2SIRT1SIRT3SIRT5HDAC8 | |
| SCHEMBL22034417 | 0.75 | SIRT5 (0.69) | SIRT2SIRT1SIRT3SIRT5HDAC8 | |
| SCHEMBL22034415 | 0.75 | SIRT5 (0.69) | SIRT2SIRT1SIRT3SIRT5HDAC8 | |
| SCHEMBL4163972 | 0.74 | TACR1 (0.64) | CTSSCTSLCTSBCTSKTACR1 | |
| SCHEMBL7970776 | 0.74 | CTSL (0.65) | CTSSCTSLCTSBCTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492541-B2 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGESELLSCHAFT (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2002-04-18 | — | — | US | disclosed |
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | DEGUSSA-HULS AKTIENGENSELLSCHAFT | 2001-09-27 | — | — | US | disclosed |
| US-6281364-B1 | CYCLIZATION | DEGUSSA-HULS AG (DE) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025109-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | SIRT2 2257/4885SIRT1 3918/4885CTSS 1368/4885 |
| US-20020045763-A1 | Process for the preparation of 3-amino-2-oxo-pyrrolidines, novel intermediates and their use | AAAS, IL4I1, PGLS | SIRT2 2257/4885SIRT1 3918/4885CTSS 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.